ID | 1124 |
Name of the vaccine | Menactra |
Microbe | Bacteria |
Disease name | Meningococcal disease |
Name of bacteria | Neisseria meningitidis |
Type of vaccine | Inactivated |
Nucleic acid content | DNA |
Age | 9 months to 55 years |
Description of the vaccine | Meningococcal (Groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine. |
Name of the manufacturer | Sanofi Pasteur Inc. |
Name of the manufacturing country | United States |
Year of manufacture | 2005 |
Clinical Phase status | Approved |
Bacterial strain | Gram-negative diplococcus. |
Efficacy | Was inferred from the immunologic equivalence to Menomune – A/C/Y/W-135 vaccine as assessed by SBA. |
Vaccine formulation | Solution supplied in 0.5 mL single-dose vials. |
Dosage | Primary Vaccination:
Children 9 to 23 months : Two doses, three months apart.
Individuals 2 to 55 years: A single dose.
Booster Vaccination:
Individuals 15 to 55 years : single booster dose for those at continued risk for meningococcal disease, after 4 years have elapsed. |
Mechanism of action | Production of bactericidal antibodies specific to the capsular polysaccharides of serogroups A, C, Y and W-135. |
Route of administration | Intramuscular |
Indications | To prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. It does not prevent N meningitidis serogroup B disease. |
Export | NA |
Approval | US FDA |
Adjuvant | NA |
Repurposing | NA |
Side effects of vaccine | Infants and toddlers 9 and 12 months : injection site tenderness, erythema, swelling, irritability, abnormal crying, drowsiness, appetite loss, vomiting, and fever.
Individuals 2 -55 years : injection site pain, redness, induration, swelling, anorexia, diarrhoea, irritability, headache, fatigue, malaise and arthralgia. |
Post vaccination | NA |
Dose type | Both |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.fda.gov/media/75619/download |
Other name | NA |
Additional Links | NA
|